AUROPHARMA

Aurobindo Pharma Limited is one of India’s large pharmaceutical companies with strong presence in generic medicines, APIs, and specialty pharma, exporting to 150+ countries with a strong focus on the US and Europe markets. Market Cap: ₹75,000+ Cr Revenue: ₹3,31,800 Cr annually Net Profit: ₹3,487 Cr EPS: ₹60 Debt/Equity: 0.22 (low leverage) The company has a diversified product portfolio including antibiotics, antiretrovirals, cardiovascular drugs, and injectables. Revenue & Profitability Revenue growth steady but not very high in recent quarters. Operating margin around 15–16%. Net profit margin 10.5%. 👉 Indicates stable but moderate profitability. Valuation P/E: 21–22 Forward P/E: 18 Sector P/E: 24 👉 Stock is slightly undervalued compared with pharma sector peers.